Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572893 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04572893 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 41 participants.
The verdict
NCT04572893, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
Interventions
- DRUG danicamtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572893
The ClinicalTrials.gov registry entry for NCT04572893 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which danicamtiv is the first listed.
NCT04572893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04572893 about?
NCT04572893 is a clinical study titled "Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities". The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
What is the current status of trial NCT04572893?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2020-08-04. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT04572893?
The interventions under investigation include: danicamtiv (DRUG).
Who is sponsoring clinical trial NCT04572893?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.